Neurofibroma clinical trials

The registry lists 33 studies for Neurofibroma across 8 countries. 9 are recruiting or about to start. 5 of them are mainly about Neurofibroma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 5 narrower conditions too, such as Neurofibromatosis 1: 351 studies, 80 open.

Get an email when these change. Save the Neurofibroma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 14
Recruiting: 7
Active, not recruiting: 4
Terminated: 4
Enrolling by invitation: 2
Status unknown: 1

Phase

Phase 2: 11
Phase 1: 6
Early Phase 1: 2

Where

United States: 27
Belgium: 1
France: 1
Germany: 1
China: 1
Russia: 1

Who runs them

National Cancer Institute (NCI) (6) · Johns Hopkins University (3) · The University of Texas Health Science Center, Houston (2) · University of Alabama at Birmingham (2) · Massachusetts General Hospital (2) · AstraZeneca (1) · KU Leuven (1) · Burzynski Research Institute (1)

What is being tested here

Drugs under test in Neurofibroma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	All
Deoxycholic Acid	1	1
Talimogene laherparepvec	1	1
Mirdametinib	0	2
Binimetinib	0	1
Everolimus	0	1
Peginterferon alfa-2b	0	1
Celecoxib	0	1
Temozolomide	0	1
Vincristine	0	1
Tipifarnib	0	1

Coming up

0phase 3 studies under way

5studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 5

Dec 2026Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 · Johns Hopkins University
Feb 2027Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs) · Massachusetts General Hospital
Mar 2027Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study · National Cancer Institute (NCI)
Jun 2027Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1 · Ann & Robert H Lurie Children's Hospital of Chicago
Nov 2027Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF). · Johns Hopkins University

Who these studies take

Of the 7 Neurofibroma studies recruiting now, 4 (57%) set no upper age limit and 0 (0%) stop at 75 or younger. 3 (43%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (14%) take healthy volunteers.

Recruiting studies that take each age, of 7
Age	Women	Men
10	3 (43%)	3 (43%)
18	7 (100%)	7 (100%)
30	7 (100%)	7 (100%)
40	7 (100%)	7 (100%)
50	7 (100%)	7 (100%)
65	7 (100%)	7 (100%)
75	7 (100%)	7 (100%)
85	6 (86%)	6 (86%)

Across all 33 studies, recruiting or not: 24% stop at 75 or younger and 21% at 65; 58% take children; 0% are for women only and 0% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 33 of 33. search them.